In Vivo Star Anti-Human CD64 (FcγRI) Antibody
英诺赛图(InnoCyto)的 In Vivo Star Anti-Human CD64 (FcγRI) Antibody(克隆 H22-hg1SL) 为人源 IgG1 Fc Silent Kappa 抗体,靶向 CD64(别名 FCGR1A 等)。提供 1 mg、5 mg、25 mg 规格,目录价 ¥1,085 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 In Vivo Star Anti-Human CD64 (FcγRI) Antibody(克隆 H22-hg1SL) 为人源 IgG1 Fc Silent Kappa 抗体,靶向 CD64(别名 FCGR1A 等)。提供 1 mg、5 mg、25 mg 规格,目录价 ¥1,085 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
517701 | 1 mg | ¥1,085
517702 | 5 mg | ¥2,712
517703 | 25 mg | ¥7,458
517801 | 1 mg | ¥1,085
517802 | 5 mg | ¥2,712
517803 | 25 mg | ¥7,458
Product Details
Application|Direct ELISA, functional assay, Flow Cytometry
Product Description|In vivo Grade Recombinant Anti-human CD64 Monoclonal Antibody
Regulatory Status|RUO
Endotoxin
Storage Conditions|4ºC
Recommended Usage|This product is suitable in in vitro functional assays or in vivo on human cells used in animal models. Optimal amounts need to be determined empirically for each experiment.
See All Formats|Clone H22-hg1SL
Background Information
CD64, also known as Fc gamma receptor I (FcγRI), is a high-affinity receptor for immunoglobulin G (IgG) and plays a central role in antibody-mediated immune responses. It is primarily expressed on myeloid lineage cells, including monocytes, macrophages, dendritic cells, and activated neutrophils. Through its ability to bind IgG-opsonized targets, CD64 enables these cells to detect, internalize, and eliminate pathogens and immune complexes, making it a key link between the adaptive humoral immune response and innate effector functions.
Structurally, CD64 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. Its extracellular region consists of three Ig-like domains, which confer its uniquely high affinity for the Fc portion of IgG, allowing it to bind monomeric IgG in addition to immune complexes. CD64 has a short cytoplasmic tail that lacks intrinsic signaling motifs and therefore associates non-covalently with the Fc receptor common γ-chain (FcRγ). This accessory chain contains immunoreceptor tyrosine-based activation motifs (ITAMs) that are essential for signal transduction following receptor engagement.
The principal ligands for CD64 are IgG antibodies, with particularly strong binding to human IgG1 and IgG3 subclasses. When CD64 binds IgG-coated microbes, tumor cells, or immune complexes, it triggers intracellular signaling through FcRγ, leading to phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), production of reactive oxygen species, and secretion of pro-inflammatory cytokines. Through these mechanisms, CD64 contributes to host defense against infection and to the clearance of antibody-tagged targets.
CD64 expression and function are implicated in several disease contexts. In infectious and inflammatory diseases, CD64 is strongly upregulated on neutrophils and monocytes in response to cytokines such as interferon-γ. Neutrophil CD64 expression has become a widely used biomarker for systemic bacterial infection and sepsis, reflecting heightened innate immune activation. In autoimmune diseases, excessive engagement of CD64 by immune complexes can contribute to chronic inflammation and tissue damage. CD64 is also expressed on tumor-associated macrophages, where it may influence antibody-based antitumor immunity.
Therapeutically, CD64 has attracted interest as both a biomarker and a potential target. Its restricted expression pattern on myeloid cells makes it an appealing target for antibody-drug conjugates or immunotoxins aimed at selectively depleting pathogenic macrophages in cancer or inflammatory disease. In addition, the effectiveness of many therapeutic antibodies relies in part on Fcγ receptor engagement, and CD64 expression levels can influence clinical responses. As a result, CD64 remains an important focus in immunology, diagnostics, and the design of next-generation antibody therapies.
Data Sheets
Cat # Size Price Quantity 5178011 mg Add to Cart5178025 mg Add to Cart51780325 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). In Vivo Star Anti-Human CD64 (FcγRI) Antibody(517801)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-human-cd64-fc-ri-antibody-517801.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Human CD64 (FcγRI) Antibody(517801). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-human-cd64-fc-ri-antibody-517801.html
@misc{biocsp_item_in_vivo_star_anti_human_cd64_fc_ri_antibody_517801,
title = {In Vivo Star Anti-Human CD64 (FcγRI) Antibody(517801)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/in-vivo-star-anti-human-cd64-fc-ri-antibody-517801.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源